About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline
LOG IN
LOG IN

2 Nanotech. L. & Bus. 367 (2005)
The Nanotech Unversity Spinout Company: Strategies for Licensing, Developing, Commercializing and Financing Nanotechnology

handle is hein.journals/nantechlb2 and id is 373 raw text is: The Nanotech University Spinout Company: Strategies for Licensing, Developing, Commercializing and Financing Nanotechnology JEFF STEWART ABSTRACT The current commercial path for nanotechnology ventures mirrors the early evolution of the biotechnology industry, allowing similar strategies toward technology commercialization and investment opportunities. I While this premise certainly rings true for the most part, there are some important differences between the commercial paths of nanotechnology ventures and ventures in the biotechnology industry. In this article, Jeff Stewart outlines strategies for licensing, developing, commercializing and financing nanotechnology. By comparing the experiences of university biotechnology spinout companies to spinouts in the nanotechnology context, Stewart offers some empirical lessons for dealing with the nanotechnology university spinout company. Particular attention is paid to licensing agreements and the role of the university nanotechnology scientist in the process, financing and product strategies. 1. INTRODUCTION T he biotechnology industry is a source of strategies in licensing, developing, commercializing and financing nanotechnology because nanotechnology and biotechnology have the following features in common: New applications in biotechnology and nanotechnology are often dependent upon intellectual property (IP) that springs from the university, corporate or national lab. * Research and development (R&D) is costly, complex and uncertain. Jeff Stewart is Chairman and a founder of NanoVici, Inc., a nanotherapeutics company currently in negotiations with a university to in-license, finance, develop and commercialize nanotechnology for biomedical applications. For more information, please visit http://i-innov8.com. Mr. Stewart may also be contacted at Jeff.Stewart@agg.com. This article was written in memory of BAS and in gratitude to HBS and RB. Robert Paull, Josh Wolfe, Peter Hebert & Michael Sinkula, Investing in Nanotechnology, 21 NATURE BIOTECH. 1144-47 (2003). NANOTECHNOLOGY LAW & BUSmiESS - NOVEMBER/DECEMBER 2005 365

What Is HeinOnline?

HeinOnline is a subscription-based resource containing thousands of academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.



Short-term subscription options include 24 hours, 48 hours, or 1 week to HeinOnline.

Purchase Access

Contact us for annual subscription options:

Contact Us

Already a HeinOnline Subscriber?

Log In

profiles profiles most